Thanks to the exceptional mobilisation of Téléthon, AFM-Téléthon has become a major stakeholder in biomedical research into rare diseases in France and the world. It is currently supporting 37 clinical trials, ongoing and in development, concerning rare sight, blood, brain, immune system and muscle diseases. Via its Généthon laboratory, AFM-Téléthon is able to design, produce and test its own innovative therapy drugs. It aims to make the first gene and cell therapy drugs, for diseases that are currently incurable, available to as many people as possible.
The Téléthon 2015 will take place on 04 and 05 December.